Polymorphisms in the lcrV gene of Yersinia enterocolitica and their effect on plague protective immunity

Infection and Immunity

Volumn 80, Issue 4, 2012, Pages 1572-1582

  Miller, Nathan C ^a,b   Quenee, Lauriane E ^a,b   Elli, Derek ^a,b   Ciletti, Nancy A ^a,b   Schneewind, Olaf ^a,b  

^a ARGONNE NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; LCRV PROTEIN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; LCRV PROTEIN, YERSINIA; OUTER MEMBRANE PROTEIN; PLAGUE VACCINE; PORE FORMING CYTOTOXIC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CONTROLLED STUDY; DNA POLYMORPHISM; GENE EXPRESSION; LCRV GENE; MACROPHAGE; MOUSE; NONHUMAN; PLAGUE; PLASMID; PRIORITY JOURNAL; TYPE III SECRETION SYSTEM; YERSINIA ENTEROCOLITICA; AMINO ACID SEQUENCE; ANIMAL; BACTERIAL SECRETION SYSTEM; BAGG ALBINO MOUSE; CELL LINE; CHEMISTRY; CLASSIFICATION; GENETICS; HELA CELL; HUMAN; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PATHOGENICITY; SEQUENCE ALIGNMENT; SINGLE NUCLEOTIDE POLYMORPHISM; YERSINIA PESTIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL SECRETION SYSTEMS; CELL LINE; HELA CELLS; HUMANS; MACROPHAGES; MICE; MICE, INBRED BALB C; PLAGUE; PLAGUE VACCINE; POLYMORPHISM, SINGLE NUCLEOTIDE; PORE FORMING CYTOTOXIC PROTEINS; SEQUENCE ALIGNMENT; YERSINIA ENTEROCOLITICA; YERSINIA PESTIS;

EID: 84860790748     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.05637-11     Document Type: Article

References (61)

1. Anderson DA, et al. 2009. Pneumonic plague pathogenesis and immunity in brown Norway rats. Am. J. Pathol. 174:910 -921.
2. Autenrieth IB, Beer M, Bohn E, Kaufmann SH, Heesemann J. 1994. Immune responses to Yersinia enterocolitica in susceptible BALB/c and resistant C57BL/6 mice: an essential role for gamma interferon. Infect. Immun. 62:2590-2599.
3. Baker EE, Sommer H, Foster LE, Meyer E, Meyer KF. 1947. Antigenic structure of Pasteurella pestis and the isolation of a crystalline antigen. Proc. Soc. Exp. Biol. 64:139 -141.
4. Baker EE, Sommer H, Foster LE, Meyer E, Meyer KF. 1952. Studies on immunization against plague. I. The isolation and characterization of the soluble antigen of Pasteurella pestis. J. Immunol. 68:131-145.
5. Begier EM, et al. 2006. Pneumonic plague cluster, Uganda, 2004. Emerg. Infect. Dis. 12:460-467.
6. Boisier P, et al. 2002. Epidemiologic features of four successive annual outbreaks of bubonic plague in Mahajanga, Madagascar. Emerg. Infect. Dis. 8:311-316.
7. Boland A, et al. 1996. Status of YopM and YopN in the Yersinia yop virulon: YopM of Y. enterocolitica is internalized inside the cytosol of PU5-1.8 macrophages by the YopB, D,Ndelivery apparatus. EMBOJ. 15:5191-5201.
8. Broz P, et al. 2007. Function and molecular architecture of the Yersinia injectisome tip complex. Mol. Microbiol. 65:1311-1320.
9. Brubaker RR. 1969. Mutation rate to non-pigmentation in Pasteurella pestis. J. Bacteriol. 98:1404 -1406.
10. Burrows TW. 1956. An antigen determining virulence in Pasteurella pestis. Nature 177:426-427.
11. Burrows TW. 1957. Virulence of Pasteurella pestis. Nature 179:1246-1247.
12. Burrows TW, Bacon GA. 1958. The effect of loss of different virulence determinants on the virulence and immunogenicity of strains of Pasteurella pestis. Br. J. Exp. Pathol. 39:278 -291.
13. Butler T. 1995. Yersinia species, p 1748-1756. In Mandell GL, Douglas RG, Bennett JE (ed), Infectious diseases, 5th ed. Churchill Livingstone, New York, NY.
14. Cheng LW, Anderson DM, Schneewind O. 1997. Two independent type III secretion mechanisms for YopE in Yersinia enterocolitica. Mol. Microbiol. 24:757-765.
15. Cornelis GR. 2006. The type III injectisome. Nat. Rev. Microbiol. 4:811-825.
16. Cornelis GR. 2002. Yersinia type III secretion: send in the effectors. J. Cell Biol. 158:401-408.
17. Cornelis GR, et al. 1998. The virulence plasmid of Yersinia, an antihost genome. Microbiol. Mol. Biol. Rev. 62:1315-1352.
18. Cornelis GR, Colson C. 1975. Restriction of DNA in Yersinia enterocolitica detected by the recipient ability for a derepressed R factor from Escherichia coli. J. Gen. Microbiol. 87:285-291.
19. Cornelius CA, Quenee LE, Elli D, Ciletti NA, Schneewind O. 2008. V10 subunit vaccine protects cynomolgus macaques from lethal pneumonic plague. Infect. Immun. 76:5588-5597.
20. Cornelius CA, Quenee LE, Elli D, Ciletti NA, Schneewind O. 2009. Yersinia pestis IS1541 transposition provides for escape from plague immunity. Infect. Immun. 77:1807-1816.
21. DeBord K, Lee VT, Schneewind O. 2001. On the role of LcrG and LcrV during the type III targeting of effector Yops by Yersinia enterocolitica. J. Bacteriol. 183:4588-4598.
22. DeBord KL, et al. 2006. Immunogenicity and protective immunity against bubonic and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV. Infect. Immun. 74:4910-4914.
23. DePaolo RW, et al. 2008. TLR6 drives differentiation of tolerogenic dendritic cells and contributes to LcrV-mediated plague pathogenesis. Cell Host Microbe 4:350 -361.
24. Ellison DW, Lawrenz MB, Miller VL. 2004. Invasin and beyond: regulation of Yersinia virulence by RovA. Trends Microbiol. 12:296 -300.
25. Friedlander AM, et al. 1995. Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis. Clin. Infect. Dis. 21:S178-S181.
26. Goure J, Broz P, Attree O, Cornelius GR, Attree I. 2005. Protective anti-V antibodies inhibit Pseudomonas and Yersinia translocon assembly within host membranes. J. Infect. Dis. 192:218 -225.
27. Hakansson S, Bergman T, Vanooteghem J-C, Cornelis G, Wolf-Watz H. 1993. YopB and YopD constitute a novel class of Yersinia Yop proteins. Infect. Immun. 61:71-80.
28. Hill J, et al. 2009. N255 is a key residue for recognition by a monoclonal antibody which protects against Yersinia pestis infection. Vaccine 27: 7073-7079.
29. Inglesby TV, et al. 2000. Plague as a biological weapon: medical and public health management. JAMA 283:2281-2290.
30. Inglesby TV, Grossman R, O'Toole T. 2001. A plague on your city: observations from TOPOFF. Clin. Infect. Dis. 32:436-445.
31. Jacobs MK. 2004. The history of biologic warfare and bioterrorism Dermatol. Clin. 22:231-246.
32. Lee VT, Anderson DM, Schneewind O. 1998. Targeting of Yersinia Yop proteins into the cytosol of HeLa cells: one-step translocation of YopE across bacterial and eukaryotic membranes is dependent on SycE chaperone. Mol. Microbiol. 28:593-601.
33. Lee VT, Tam C, Schneewind O. 2000. LcrV, a substrate for Yersinia enterocolitica type III secretion, is required for toxin targeting into the cytosol of HeLa cells. J. Biol. Chem. 275:36869 -36875.
34. Marketon MM, DePaolo RW, DeBord KL, Jabri B, Schneewind O. 2005. Plague bacteria target immune cells during infection. Science 309:1739-1741.
35. Meyer KF, Smith G, Foster L, Brookman M, Sung MH. 1974. Live, attenuated Yersinia pestis vaccine: virulent in non-human primates, harmless to guinea pigs. J. Infect. Dis. 129:S85-S112.
36. Motin VL, Nakajima R, Smirvov GB, Brubaker RR. 1994. Passive immunity to yersiniae mediated by anti-recombinant V antigen and Protein A-V antigen fusion peptide. Infect. Immun. 62:4192- 4201.
37. Mueller CA, Broz P, Cornelis GR. 2008. The type III secretion system tip complex and translocon. Mol. Microbiol. 68:1085-1095.
38. Mueller CA, et al. 2005. The V-antigen of Yersinia forms a distinct structure at the tip of injectisome needles. Science 310:674-676.
39. Nakajima R, Brubaker RR. 1993. Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha. Infect. Immun. 61:23-31.
40. Nakajima R, Motin VL, Brubaker RR. 1995. Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunization. Infect. Immun. 63:3021-3029.
41. 2+ response. J. Bacteriol. 179:1307-1316.
42. Overheim KA, et al. 2005. LcrV plague vaccine with altered immunomodulatory properties. Infect. Immun. 73:5152-5159.
43. Perry RD, Fetherston JD. 1997. Yersinia pestis: etiologic agent of plague. Clin. Microbiol. Rev. 10:35-66.
44. 2+ response operon encodes the V antigen of Yersinia pestis. Infect. Immun. 54:428-434.
45. Petterson J, et al. 1999. The V-antigen of Yersinia is surface exposed before target cell contact and involved in virulence protein translocation. Mol. Microbiol. 32:961-976.
46. Quenee L, Cornelius CA, Ciletti NA, Elli D, Schneewind O. 2008. Yersinia pestis caf1 (F1) variants and the limits of plague vaccine protection. Infect. Immun. 76:2025-2036.
47. Quenee LE, et al. 2010. Amino acid residues 196-225 of LcrV represent a plague protective epitope. Vaccine 28:1870 -1876.
48. Quenee LE, Ciletti NA, Elli D, Hermanas T, Schneewind O. 2011. Prevention of pneumonic plague in mice, rats, guinea pigs and nonhuman primates with clinical grade rV10, rV10-2, or F1-V vaccines. Vaccine 29:6572-6583.
49. Quenee LE, Schneewind O. 2009. Plague vaccines and the molecular basis of immunity against Yersinia pestis. Hum. Vaccines 5:817- 823.
50. Roggenkamp A, Geiger AM, Leitritz L, Kessler A, Heesemann J. 1997. Passive immunity to infection with Yersinia spp. mediated by recombinant V antigen is dependent on polymorphism of V antigen. Infect. Immun. 65:446-451.
51. Rosqvist R, Forsberg A, Rimpilainen M, Bergman T, Wolf-Watz H. 1990. The cytotoxic protein YopE of yersinia obstructs the primary host defense. Mol. Microbiol. 4:657-667.
52. Rosqvist R, Magnusson K-E, Wolf-Watz H. 1994. Target cell contact triggers expression and polarized transfer of Yersinia YopE cytotoxin into mammalian cells. EMBO J. 13:964 -972.
53. Simond PL. 1898. La propagation de la peste. Ann. Inst. Pasteur 12:625-687.
54. 2+ response, and virulence of Yersinia pestis. J. Bacteriol. 177:2530 -2542.
55. Sorg JA, Miller NC, Marketon MM, Schneewind O. 2005. Rejection of impassable substrates by Yersinia type III secretion machines. J. Bacteriol. 187:7090-7102.
56. Weeks S, Hill J, Friedlander A, Welkos S. 2002. Anti-V antigen antibody protects macrophages from Yersinia pestis-induced cell death and promotes phagocytosis. Microb. Pathog. 32:227-237.
57. Williamson ED, et al. 2005. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect. Immun. 73:3598- 3608.
58. Worsham PL, Stein MP, Welkos SL. 1995. Construction of defined F1 negative mutants of virulent Yersinia pestis. Contrib. Microbiol. Immunol. 13:325-328.
59. Yersin A. 1894. La peste bubonique a' Hong-Kong. Ann. Inst. Pasteur 2:428-430.
60. Zauberman A, et al. 2008. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague. Vaccine 26: 1616-1625.
61. Zavialov AV, et al. 2003. Structure and biogenesis of the capsular F1 antigen from Yersinia pestis: preserved folding energy drives fiber formation. Cell 113:587-596.